Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  Medical DevicesIssue 654

Smartphones Boost Diabetes Outcomes

Patients who received mobile-based diabetes care, including a wireless glucometer and a smartphone containing a personalized care plan, showed lower A1C levels at six months compared with those who had usual care....
Advertisement

Results from a three-year clinical trial show the use of smartphones help diabetic patients control their disease.

The published peer-reviewed study, was conducted by Palo Alto Foundation Medical Group serving northern California. About 400 patients with uncontrolled diabetes participated in the trial, funded through the Agency for Healthcare Research and Quality.

Half of the patients were in an "intervention group" (INT) and given a wireless glucometer and a smartphone loaded with a personalized care plan for a year, along with access to a diabetes care manager and educational messages. The other patients were in a "usual care" (UC) control group with access to regular clinic care. The trial paid for a data plan for those given a smartphone.

After six months, patients in the intervention group with smartphones and a wireless home glucometer had significantly reduced A1C levels compared with patients receiving usual care, but the differences were not significantly different after 12 months. However, intervention group patients had significantly better control of their LDL cholesterol at 12 months, and initiated many more online messages to providers during their time in the study.

"Regarding medication management, there was a significant difference in the two groups in the number of medication orders to initiate a new medication or change an existing medication (1,312 INT vs. 1,158 UC), and the number of insulin orders," according to the study.

Intensification of diabetes treatment, such as a new treatment or increase in insulin dose, also was higher in the INT group. "For patients already receiving insulin, the INT group significantly increased the doses of insulin (227 vs. 90)." Yet, there were not significant differences in the number of total physician visits between the two groups.

Researchers also found that patients on mobile-based care had better control of their bad cholesterol levels and were more likely to communicate online with their health care providers than those in the control group. The results appear in the Journal of the American Medical Information

Journal of the American Medical Informatics Association, Nov 2012

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 29 November, 2012 and appeared in  Medical DevicesIssue 654

Past five issues: SGLT-2 Inhibitors Special Edition July 2015 | Diabetes Clinical Mastery Series Issue 251 | Issue 791 | Diabetes Clinical Mastery Series Issue 250 | GLP-1 Special Editions July 2015 |

2015 Most Popular Articles:

Self-Monitoring of Blood Glucose: The Patient's Perspective
Posted July 10, 2015
The Impact of Glucagon-Like Peptide 1 Receptor Agonists on Weight Reduction
Posted July 10, 2015
Diet That Mimics Fasting Appears to Slow Aging
Posted July 03, 2015
Vitamin D3 Supplementation and Weight Loss Prevent Cancer in Older Women
Posted July 10, 2015
Evaluation of Cellphone Application that Records Readings from Glucometer
Posted July 10, 2015
GLP-1 Receptor Agonists Reduce Bone Loss During Weight Loss
Posted July 17, 2015
Metformin May Increase Mortality in Advanced CKD among Type 2 Patients
Posted July 10, 2015
Can the Insulin Patch Become a Reality?
Posted July 03, 2015
New Evidence Suggests Pioglitazone Reduces Dementia Risk 42%
Posted July 03, 2015
Ancestral Diets Can Determine Vulnerability to Type 2 Diabetes
Posted July 17, 2015


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Do you have any patients on a dual therapy of a DPP-4 and a SGLT-2 who have reached their goal A1c?

CME/CE of the Week
Dr. Robert P. Giugliano and Dr. Stephen Wiviott

Category: Cardiology
Credits:
 1